Leerink Partners Initiates Coverage On Scribe Therapeutics with Outperform Rating, Announces Price Target of $37

Benzinga Newsdesk www.benzinga.com Positive 54.2%

Neg 0% Neu 0% Pos 54.2%

Leerink Partners analyst David Risinger initiates coverage on Scribe Therapeutics (NASDAQ:SCTX) with a Outperform rating and announces Price Target of $37.